Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
ID: 350263Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350263

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-296.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation," aimed at exploring innovative interventions for HIV treatment. The primary objective is to identify cure strategies that can be administered at the start of combination antiretroviral therapy (cART) or after an analytical treatment interruption (ATI), with the goal of achieving sustained treatment-free remission. This initiative supports R21 applications for exploratory research, with a maximum budget of $275,000 and a project duration of up to two years, emphasizing the importance of diversity in research teams. Interested applicants should note that the application deadline is September 7, 2026, and can find further details at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-296-Full-Announcement.html
    PAR-23-296.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity aimed at exploring HIV cure strategies in relation to the initiation of combination antiretroviral therapy (cART). The primary goal is to identify interventions that can enhance treatment-free remission rates when administered at the onset of cART or after an analytical treatment interruption (ATI). This Notice of Funding Opportunity (NOFO) invites R21 applications, supporting shorter-term exploratory research (up to two years) with a maximum budget of $275,000. The research should focus on novel interventions and basic research into HIV reservoir dynamics and decay, as well as optimizing immune responses against HIV. All applications must comply with instructions from the NIH Grants Policy Statement, and diversity in research teams is encouraged. This initiative highlights the NIH's commitment to addressing HIV through innovative research while fostering scientific diversity and inclusion. The announcements regarding application due dates range from December 7, 2023, with a final expiration set for September 8, 2026, ensuring ample opportunity for submission.
    Similar Opportunities
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt)" aimed at supporting the development of long-acting/sustained release (LA/SR) technologies for the prevention and treatment of HIV and associated co-infections such as tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). This initiative seeks to fund preclinical activities that will advance these technologies toward submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA), with a focus on ensuring safety and efficacy through rigorous studies. The program is particularly significant as it addresses public health challenges related to infectious diseases that disproportionately affect individuals living with HIV, and it will provide approximately $4 million to support 3-5 awards, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)" aimed at investigating the mechanisms by which T-cells contribute to HIV's neurological implications. This initiative seeks to enhance understanding of HIV's seeding and persistence in the central nervous system (CNS), as well as its associated neurological disorders, encouraging research that explores T-cell neuro-invasion and potential therapeutic strategies. The total funding available is $5.5 million, with individual budgets capped at $275,000 over a two-year period, and applications are encouraged from a diverse range of eligible organizations, including higher education institutions and non-profits. Interested applicants should note that the submission deadline is March 18, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for further details.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models," aimed at supporting preclinical research on HIV/AIDS conducted by early-stage investigators with at least two years of postdoctoral experience. This funding initiative encourages innovative research approaches utilizing NHP models to develop next-generation therapies and strategies for HIV cure, aligning with the NIH Strategic Plan priorities for HIV research. Eligible applicants can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years, and must adhere to specific application procedures. The application deadline is September 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.